Pregled bibliografske jedinice broj: 483323
Pharmacoeconomic Modelling of Alzheimer`s Disease – Assessment of Memantine in Treating Moderate to Severe Alzheimer Patients
Pharmacoeconomic Modelling of Alzheimer`s Disease – Assessment of Memantine in Treating Moderate to Severe Alzheimer Patients // Neurologia Croatica 59 (Suppl. 2) - Abstracts of the 5th Croatian Congress on Alzheimer’s Disease with International Participation / Šimić, Goran ; Mimica, Ninoslav (ur.).
Zagreb: Denona, 2010. str. 43-43 (predavanje, domaća recenzija, sažetak, znanstveni)
CROSBI ID: 483323 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pharmacoeconomic Modelling of Alzheimer`s Disease – Assessment of Memantine in Treating Moderate to Severe Alzheimer Patients
Autori
Benković, Vanesa ; Mimica, Ninoslav ; Stevanović, Ranko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Neurologia Croatica 59 (Suppl. 2) - Abstracts of the 5th Croatian Congress on Alzheimer’s Disease with International Participation
/ Šimić, Goran ; Mimica, Ninoslav - Zagreb : Denona, 2010, 43-43
Skup
5th Croatian Congress on Alzheimer's Disease with International Participation
Mjesto i datum
Zadar, Hrvatska, 22.09.2010. - 25.09.2010
Vrsta sudjelovanja
Predavanje
Vrsta recenzije
Domaća recenzija
Ključne riječi
Pharmacoeconomic Modelling; Alzheimer`s Disease; Memantine; Moderate; Severe
Sažetak
In treating of moderate to severe Alzheimer patients, N-methyl D-aspartat antagonist memantine has demonstarated better results and correlations with decreased hospitalization rate, thus decreasing total health costs. Most of pharmacoeconomic studies for this disease consider societal perspective using cost effectiveness principle and QUALY parameters. This paper considers payer perspective (Croatian Department for Health Insurance) and takes into account direct cost of the disease as requested in Croatian guidelines for drugs reimbursement. Due to lack of (inaccurate) epidemiological data, authors have undertaken further data search : the paper demonstrates cost variables taken from Croatian real life environment of treating Alzheimer patients. The aim of the paper was to assess direct cost of illness with and without treatment with memantine, through three year perspective. Markov model method was created for Croatian case to assess effect of the drug on hospitalization frequency and other direct treatment costs. Model stability was tested with Monte Carlo simulations. Results demonstrate memantine domination in terms of efficiency and cost reduction, bringing cost saving not only to health budget of the payer, but also to other hospital related costs.
Izvorni jezik
Engleski
Znanstvena područja
Javno zdravstvo i zdravstvena zaštita
Napomena
Indexed / Abstracted in: Neuroscience Citation Index ; EMBASE / Excerpta Medica
POVEZANOST RADA
Projekti:
005-1080315-0303 - Odrednice jednakosti i pravičnosti u zdravlju i zdravstvenoj zaštiti u Hrvatskoj (Stevanović, Ranko, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče